17:25 EST Cytokinetics (CYTK) files automatic mixed securities shelf
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTK:
- Cytokinetics reports Q4 EPS ($1.26), consensus ($1.17)
- Cytokinetics (CYTK) Q4 Earnings Cheat Sheet
- Buy Recommendation for Cytokinetics Based on Competitive Advantage in Cardiovascular Treatments
- Cytokinetics rumor highlighted in Betaville alert
- Positive Outlook for Cytokinetics: Buy Rating Based on Aficamten’s Advantages and Upcoming Catalysts